ProMedDx

What ProMedDx does

ProMedDx operates a biospecimens and biomarker services business centered on one of the larger commercial biobanks in the industry, containing over 10 million specimens including viable cells, tissues, blood and biofluid derivatives, remnant diagnostic specimens, and NGS-characterized specimens. The business sits within the broader Precision Medicine Group, LLC (doing business as Precision for Medicine), an integrated precision medicine and contract research organization (CRO) that combines clinical trial management, specialty laboratory services, and biospecimen supply under a platform-plus-modules architecture. Underlying capabilities include IRB-approved collection protocols, an international network of 150 clinical collection sites spanning the Americas, Europe, and Asia-Pacific, integrated processing laboratories co-located with donor centers, and pathology services with in-house pathologists supporting immunohistochemistry, multiplex immunofluorescence, and digital pathology. The NGS-characterized library contains 13,000+ specimens across more than 20 oncology indications, complete with variant data, surgical pathology reports, and H&E images, positioning the inventory as both a research resource and a potential AI training asset for computational pathology.

The company serves pharmaceutical and life sciences companies as its primary customer segment, with academic and research institutions as a secondary segment. Use cases center on precision therapeutic development, diagnostic and companion diagnostic development, biomarker research, clinical trial support, and drug development programs in oncology, autoimmune, and infectious disease. Revenue is generated through two primary streams: catalog biospecimen product sales (one-time per-specimen transactions) and custom biospecimen collection services (professional services engagements covering donor recruitment, kitting, sample collection, logistics, and optional characterization). The go-to-market motion is enterprise field sales with a consultative approach, quote-based pricing that is not publicly disclosed, and CTAs structured as 'Request a quote' or 'Order now' on the website. Multiple certifications (CAP, CLIA, FDA registered, Medical IRB/IEC, and Good Clinical Practice) support clinical-grade compliance for regulated downstream use of the specimens.

The business is privately held and headquartered in Norton, Massachusetts (United States), founded in 1998. Firmographics indicate 11-50 employees, which appears to reflect the ProMedDx biospecimens business unit specifically rather than the full Precision for Medicine organization. Operating geographies span the Americas, Europe, and Asia-Pacific. The competitive positioning rests on the scale of the biobank, the breadth of the global collection network, the regulatory credential stack, and the integrated single-chain of custody from donor selection through delivery, though the company has not disclosed revenue, funding history, customer concentration, or M&A activity in the available data.

Name

ProMedDx

Legal name

Precision Medicine Group, LLC

Website

https://promeddx.com

Company type

Private

Founded year

1998

Operating status

Operating

Headcount range

11–50 employees

Short description

ProMedDx provides ethically sourced, clinically annotated human biospecimens and biomarker services to pharmaceutical, life sciences, and academic research clients, operating a biobank of over 10 million specimens across a 150-site global collection network.

Ownership category

akta.pro rank

Product category

Biospecimen Supply and Biobank Services

NAICS

Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)

akta.pro secondary industries

Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD), DMPK / ADME & Bioanalysis (HLAGAFAC), Clinical Data Management, Biostatistics & Statistical Programming CROs (HLAGAAAF)

Keywords

• Human biospecimens supply
• Biorepository services
• Biomarker research samples
• Clinical research specimens
• Precision medicine samples

Headquarters

HQ city

Norton

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Biospecimen Product Sales: Sale of catalog biospecimens including biofluids, tissues, viable cells, remnant diagnostic specimens, and NGS characterized specimens. Inventory includes over 10 million specimens across multiple specimen types and volumes. Matched specimens available.
2. Custom Biospecimen Collections: Custom collection services including plan development and full service execution: donor recruitment, kitting, sample collection, and logistics. Custom processing capabilities and specialty assay services to characterize and annotate specimens.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

ProMedDx supplies IRB-approved, clinically annotated human biospecimens including viable cells, tissues, blood and biofluid derivatives, remnant diagnostic specimens, and NGS-characterized specimens to pharmaceutical and life sciences organizations. The company operates an extensive biobank with over 10 million specimens and provides custom biospecimen collection services, leveraging a global network of clinical sites, integrated processing laboratories, and advanced characterization capabilities for precision therapeutic, diagnostic, and biomarker research programs.

Product overview

Precision for Medicine operates as an integrated precision medicine and contract research organization (CRO) offering a platform-plus-modules architecture. The core platform consists of three interconnected service pillars: Clinical Trial Management (CRO services), Lab Services & Translational Sciences, and Biospecimens. Clinical Trial Management encompasses project management, regulatory consulting, feasibility, monitoring, data management, biostatistics, and medical writing. Lab Services provides multi-omics, immune monitoring, flow cytometry, tissue/liquid biopsy analysis, genomics, bioanalysis, and biomarker validation. Biospecimens maintains over 10 million specimens including viable cells, tissues, blood products, and NGS-characterized specimens. Additional modules include Cell & Gene Therapy Services, Regulatory Consulting, Multi-Omics & AI Services, and specialized therapeutic area programs in oncology, autoimmune, and infectious diseases. The platform is supported by global operations across Americas, Europe, and Asia-Pacific, with a Precision Site Network and custom collection capabilities through 150 clinical sites worldwide.

Differentiator

Problem solved

Functional benefit

Products and services

• Biospecimens Catalog
• Custom Biospecimen Collections
• Clinical Trial Management
• Lab Services and Translational Sciences
• Global Clinical Operations and Precision Site Network
• Regulatory Consulting Services
• Cell and Gene Therapy Services
• Multi-Omics and AI Services

Quantifiable outcome

• 13,000+ NGS characterized oncology specimens available with variant data, surgical pathology reports, and H&E images
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature5 records

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Bio-Techne: Life-sciences tools company offering proteomics, genomics, and biomarker assay reagents (e.g., ProteinSimple, Olink-adjacent platforms). Adjacent competitor in the biomarker analytical and proteomics services space that ProMedDx serves.
• Charles River Laboratories: Major CRO and life-sciences services provider with biospecimen, safety assessment, and translational lab capabilities. While broader and preclinical-heavy, Charles River competes for the same pharma R&D wallet around biomarker and biospecimen services.
• Brooks Life Sciences (Azenta Life Sciences): Global provider of sample storage, biostorage, and biospecimen-related services with much larger scale and instrument/software platforms. Competes with ProMedDx in biobanking and sample management for pharma clients.
• Labcorp (Covance): Large clinical lab and CRO with bioanalytical, biomarker, and central lab services used by pharma and diagnostics developers. Overlaps with ProMedDx's translational lab, biomarker, and central lab capabilities, though at much greater scale.

Direct peers

• Discovery Life Sciences: Biospecimen and biomarker services provider with a large biobank, prospective collections, and specialty lab capabilities in flow cytometry, genomics, and IHC. Overlaps directly with ProMedDx on characterized biospecimens, custom collections, and translational lab services.
• SeraCare (LGC Clinical Diagnostics): Provider of biospecimen-derived reference materials, cell-line DNA, and disease-state samples for IVD and CDx development. Closely comparable to ProMedDx's NGS-characterized oncology specimens and IVD/CDx support services.
• BioIVT: One of the largest commercial providers of human biospecimens, including characterized tissues, biofluids, and matched sets for pharma and diagnostic clients. Most directly comparable to ProMedDx's catalog and custom biospecimen business across therapeutic areas.
• iSpecimen: Marketplace and biospecimen procurement platform connecting researchers with human specimens from a network of hospitals and labs. Comparable to ProMedDx's custom biospecimen sourcing model, particularly for prospective disease-state collections.
• Boca Biolistics: Specialty human biospecimen provider focused on disease-state tissues, fluids, and matched samples for research. Directly comparable to ProMedDx's catalog and prospective collection offering, particularly for oncology and infectious disease.

Emerging players

• Reprocell: Specialty provider of human tissue, biofluids, and iPSC-derived cell products for drug discovery and regenerative medicine. Comparable to ProMedDx's viable cells and custom collection business with a focus on translational research.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/promeddx-llc
• Xx.com/ProMedDx

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ProMedDx